Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The study details page now displays a 403 Forbidden error in place of the content. This indicates an access restriction and prevents viewing the study record and page navigation as before.
    Difference
    0.5%
    Check dated 2026-09-26T16:28:27.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The page now renders a 403 Forbidden error, replacing the study record content and making the trial information inaccessible to users.
    Difference
    18%
    Check dated 2026-09-19T18:31:02.000Z thumbnail image
  4. Check
    37 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.5 to v3.6.6, indicating a new release version. This update is an internal version change and does not modify the study content.
    Difference
    0.1%
    Check dated 2026-08-29T21:50:34.000Z thumbnail image
  5. Check
    58 days ago
    Change Detected
    Summary
    Core page content identifying investigators, sponsor, collaborators, and other study personnel was removed, along with multiple study record metadata sections. A new Revision: v3.6.5 tag appears, indicating a version update to the page.
    Difference
    17%
    Check dated 2026-08-08T18:14:23.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    The page's revision version was updated from v3.6.3 to v3.6.4, indicating a new deployment. This update does not modify the study details or functionality presented to users.
    Difference
    0.1%
    Check dated 2026-07-25T12:29:54.000Z thumbnail image
  7. Check
    94 days ago
    Change Detected
    Summary
    The page version was updated from v3.6.2 to v3.6.3. This represents a routine update that does not alter study information or how a user interacts with the page.
    Difference
    0.1%
    Check dated 2026-07-03T22:55:39.000Z thumbnail image

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.